Role of vascular endothelial growth factor C in classical Hodgkin lymphoma

References

• Yung L, Linch D. Hodgkin's lymphoma. Lancet 2003;361:943–951.
   PubMed Web of Science ®Google Scholar
• Gobbi PG, Ferreri AJM, Ponzoni M, et al. Hodgkin lymphoma. Crit Rev Oncol Hematol 2013;85:216–237.
   PubMed Web of Science ®Google Scholar
• Giles FJ. The vascular endothelial growth factor (VEGF) signaling pathway:a therapeutic target in patients with hematologic malignancies. Oncologist 2001;6(Suppl. 5):32–39.
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–1027.
   PubMed Web of Science ®Google Scholar
• Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997;90: 3167–3172.
   PubMed Web of Science ®Google Scholar
• Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002; 197:677–683.
   PubMed Web of Science ®Google Scholar
• Agarwal B, Naresh KN. Re: Doussis-Anagnostopoulou et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002; 197: 677–683. J Pathol 2003;201:334–335.
   PubMed Web of Science ®Google Scholar
• Mainou-Fowler T, Angus B, Miller S, et al. Microvessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leuk Lymphoma 2006;47:223–230.
   PubMed Web of Science ®Google Scholar
• Rueda A, Olmos D, Villareal V, et al. Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission. Clin Lymphoma Myeloma 2007;7:400–405.
   PubMedGoogle Scholar
• Giles FJ, Vose JM, Do KA, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 2004;28:595–604.
   PubMed Web of Science ®Google Scholar
• Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001;7:462–468.
   PubMed Web of Science ®Google Scholar
• Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007;8:464–478.
   PubMed Web of Science ®Google Scholar
• Gratzinger D. VEGF-C: putting the “lymph” back in lymphoma? Leuk Lymphoma 2009;50:311–312.
   PubMed Web of Science ®Google Scholar
• Pazgal I, Boycov O, Shpilberg O, et al. Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas. Leuk Lymphoma 2007;48:2213–2220.
   PubMed Web of Science ®Google Scholar
• Kadowaki I, Ichinohasama R, Harigae H, et al. Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br J Haematol 2005;130:869–877.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7: 1630–1636.
   PubMed Web of Science ®Google Scholar
• Weiss LM, Warnke RA, Hansmann ML, et al. Pathology of Hodgkin lymphoma. In: Hoppe RT, Mauch PM, Armitage JO, et al., editors. Hodgkin lymphoma. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. pp 43–71.
   Google Scholar
• Clipsham RC, McCabe ER. Single-tube gene-specific expression analysis by high primer density multiplex reverse transcription. Mol Genet Metab 2001;74:435–448.
   PubMed Web of Science ®Google Scholar
• Paydas S, Seydaoglu G, Ergin M, et al. The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leuk Lymphoma 2009;50:366–373.
   PubMed Web of Science ®Google Scholar
• Ganjoo KN, Moore AM, Orazi A, et al. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. J Cancer Res Clin Oncol 2008;134:381–387.
   PubMed Web of Science ®Google Scholar
• Al-Moundhri MS, Al-Shukaili A, Al-Nabhani M, et al. Measurement of circulating levels of VEGF-A, -C, and –D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World J Gastroenterol 2008;14: 3879–3883.
   PubMed Web of Science ®Google Scholar
• Naumnik W, Izycki T, Swidzińska E, et al. Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy. Oncol Res 2007;16:445–451.
   PubMed Web of Science ®Google Scholar
• Rueda A, Rifa J, Quero C, et al. High serum levels of vascular endothelial growth factor-C have a positive impact on outcome of patients with advanced diffuse large B cell lymphoma. Leuk Lymphoma 2014;55:1413–1416.
   PubMed Web of Science ®Google Scholar
• Rueda A, Sabin P, Rifa J, et al. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. Hematol Oncol 2008;26:27–32.
   PubMed Web of Science ®Google Scholar
• Jorgensen JM, Sorensen FB, Bendix K, et al. Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leuk Lymphoma 2009;50:1647–1660.
   PubMed Web of Science ®Google Scholar